Personal Protective Equipment and Antiviral Drug Use during Hospitalization for Suspected Avian or Pandemic Influenza1

• Published in: Emerging infectious diseases Vol. 13; no. 10; pp. 1541 - 1547
• Main Authors: Swaminathan, Ashwin, Martin, Rhea, Gamon, Sandi, Aboltins, Craig, Athan, Eugene, Braitberg, George, Catton, Michael G., Cooley, Louise, Dwyer, Dominic E., Edmonds, Deidre, Eisen, Damon P., Hosking, Kelly, Hughes, Andrew J., Johnson, Paul D., Maclean, Andrew V, O’Reilly, Mary, Peters, S. Erica, Stuart, Rhonda L., Moran, Rodney, Grayson, M. Lindsay
• Format: Journal Article
• Language: English; Japanese
• Published: Centers for Disease Control and Prevention 01.10.2007
• ISSN: 1080-6040; 1080-6059
• DOI: 10.3201/eid1310.070033

In a pandemic, many current national stockpiles of PPE and antiviral medications are likely inadequate. For pandemic influenza planning, realistic estimates of personal protective equipment (PPE) and antiviral medication required for hospital healthcare workers (HCWs) are vital. In this simulation study, a patient with suspected avian or pandemic influenza (API) sought treatment at 9 Australian hospital emergency departments where patient–staff interactions during the first 6 hours of hospitalization were observed. Based on World Health Organization definitions and guidelines, the mean number of “close contacts” of the API patient was 12.3 (range 6–17; 85% HCWs); mean “exposures” were 19.3 (range 15–26). Overall, 20–25 PPE sets were required per patient, with variable HCW compliance for wearing these items (93% N95 masks, 77% gowns, 83% gloves, and 73% eye protection). Up to 41% of HCW close contacts would have qualified for postexposure antiviral prophylaxis. These data indicate that many current national stockpiles of PPE and antiviral medication are likely inadequate for a pandemic.